Moderna taps Thermo Fisher for 15-year mRNA production pact for COVID vaccines and more

In the third year of the pandemic, mRNA specialist Moderna is marshaling one of its tried-and-true manufacturing partners to lock up production of its COVID shot for years to come.

Moderna and Thermo Fisher Scientific have forged a manufacturing pact to shore up production of Moderna’s COVID-19 vaccine Spikevax—plus the biotech’s other investigational mRNA products—over the next 15 years, the partners said Wednesday.